Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of Halozyme ... [Yahoo! Finance]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
The transaction was executed at an average price of $39.75 per share, resulting in a total value of $795,000. Halozyme Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. The company's proprietary enzyme technology is used in a broad range of clinical and commercial products, enhancing the delivery of injectable drugs and fluids. Warning! GuruFocus has detected 3 Warning Signs with HALO. Over the past year, Michael Labarre has sold a total of 140,000 shares of Halozyme Therapeutics Inc and has not made any purchases of the stock. The insider transaction history for the company reveals a pattern of 16 insider sells and no insider buys over the same timeframe. On the date of the insider's recent sell, shares of Halozyme Therapeutics Inc were trading at $39.75, giving the company a market capitalization of $5.033 billion. The price-earnings ratio stood at 18.81, which is below t
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- How Novo-Catalent Deal Affects Halozyme (HALO)? [Yahoo! Finance]Yahoo! Finance
- Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.MarketBeat
- Mahesh Krishnan Elected to Halozyme's Board of Directors [Yahoo! Finance]Yahoo! Finance
- Mahesh Krishnan Elected to Halozyme's Board of DirectorsPR Newswire
- Why This 1 Value Stock Could Be a Great Addition to Your Portfolio [Yahoo! Finance]Yahoo! Finance
HALO
Earnings
- 2/20/24 - Beat
HALO
Sec Filings
- 4/29/24 - Form 4
- 4/29/24 - Form 4
- 4/29/24 - Form 4
- HALO's page on the SEC website